Federal Register / Vol. 69, No. 225 / Tuesday, November 23, 2004 / Notices 68153

Washington, DC 20447, Attn: ACF 

Reports Clearance Officer. All requests 

should be identified by the title of the 

information collection. E-mail address: 

grjohnson@acf.hhs.gov.

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register.

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Attn: Desk Officer for 

ACF, E-mail address: 

Katherine_T._Astrich@omb.eop.gov.

Dated: November 16, 2004. 

Robert Sargis, 

Reports Clearance Officer.

[FR Doc. 04–25892 Filed 11–22–04; 8:45 am] 

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commerical 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel NIAID AIDS Training Grant. 

Date: December 14, 2004. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

3145, Bethesda, MD 20817, (Telephone 

Conference Call). 

Contact Person: Geetha P. Bansal, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, NIAID/NIH/DHHS, Room 3145, 

6700–B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892, (301) 402–5658, 

gbansal@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS)

Dated: November 15, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25902 Filed 11–22–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel Unsolicited Program Project 

(PO1) Application. 

Date: December 14, 2004. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700B Rockledge Drive, Bethesda, 

MD 20817, (Telephone Conference Call). 

Contact Person: John A. Bogdan, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/

NIAID, 6700B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892–7616, 301–496–2550, 

jbogdan@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS)

Dated: November 15, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25903 Filed 11–22–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Conformationally Locked 

Nucleoside Analogs

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license to practice the following 

invention as embodied in the following 

patent applications: DHHS Ref. No. E–

231–1993; U.S. Serial Number 08/

126,796, filed on September 24, 1993; 

08/311,425, filed on September 23, 

1994, U.S. Patent No. 5,629,454; 08/

818,563, filed on March 14, 1997, U.S. 

Patent No. 5,869,666; PCT (PCT/US94/

10794) filed on September 23, 1994, and 

National Stage filed in Singapore 

(9607728–4), Australia (78420/94), 

Canada (2172534), Europe (94929321.1), 

Japan (07–506691), Greece (3026166); 

DHHS Ref. No. E–100–1996; U.S. 

Provisional 60/023,565, filed on August 

7, 1996; U.S. Serial Number 08/908,724, 

filed on August 7, 1997, U.S. Patent No. 

5,840,728; PCT (PCT/US96/12800) filed 

on August 15, 1996; DHHS Ref. No. E–

249–2000; U.S. Provisional 60/220,934, 

filed on July 26, 2000; U.S. Serial 

Number 10/346,762, filed on January 15, 

2003; PCT (PCT/US01/23246) filed on 

July 24, 2001, and National Stage filed 

in Australia (2001278993), Canada 

(2417251), Europe (01951228.8) to N&N 

Scientific, having a place of business in 

Maryland but incorporated in Illinois. 

The patent rights in these inventions 

have been assigned to the United States 

of America.

DATES: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

January 24, 2005 will be considered.

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Robert M. Joynes, Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; 

Email: joynesr@od.nih.gov; Telephone: 

(301) 594–6565; Facsimile: (301) 402–

0220.

SUPPLEMENTARY INFORMATION: The 

prospective exclusive license will be